Hepatitis C DNA vaccine - ChronTech

Drug Profile

Hepatitis C DNA vaccine - ChronTech

Alternative Names: ChronVac-C; NS3/4a DNA vaccine

Latest Information Update: 23 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tripep
  • Developer ChronTech Pharma
  • Class Antivirals; DNA vaccines; Hepatitis C vaccines
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Hepatitis C

Most Recent Events

  • 23 Jul 2015 Clinical development is ongoing in Sweden
  • 01 Sep 2014 Hepatitis C vaccine technology repurchased from Avac Pharma
  • 23 Aug 2013 Hepatitis C DNA vaccine technology sold to Avac Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top